PRTA proposes capital reduction to create distributable reserves; Board recommends FOR
Rhea-AI Filing Summary
Prothena Corporation plc is asking shareholders to approve a reduction of capital to create distributable reserves at an Extraordinary General Meeting to be held on November 19, 2025 at 4:00 p.m. local time in Dublin. The Board unanimously recommends a FOR vote on Proposal No. 1, which would permit the company to convert a portion of its capital into distributable reserves that can be used for dividends, share repurchases or other corporate purposes consistent with Irish law.
The Proxy Statement will be made available primarily via the internet on or about October 7, 2025 to shareholders of record as of the September 24, 2025 Record Date. There were 53,829,928 ordinary shares outstanding as of the Record Date. Voting may be done in person, by signed proxy card, by internet, or by telephone (if printed materials are requested). Advance director nomination windows are set for October 29, 2025 through December 28, 2025, and universal proxy notices must comply by March 14, 2026. Voting results will be filed within four business days after the meeting.
Positive
- Board unanimously recommends approval of the capital reduction to create distributable reserves
- 53,829,928 ordinary shares disclosed as outstanding, providing a clear voting base
- Voting options include in-person, signed proxy, internet, and telephone (if printed materials requested) to maximize shareholder participation
- Timely disclosure commitment: voting results to be filed within four business days after the EGM
Negative
- Proxy materials delivered primarily via internet may limit immediate access for shareholders who prefer paper unless they request copies
- Approval depends on a shareholder quorum (majority of issued and outstanding shares), so the proposal is contingent on sufficient participation
Insights
Board seeks shareholder approval to create distributable reserves via capital reduction.
The requested capital reduction is a legal mechanism under Irish company law to convert paid-in capital into distributable reserves so the company can legally return capital to shareholders or effect share buybacks and dividends. The Board's unanimous recommendation signals alignment between management and the board on using balance-sheet flexibility.
Execution depends on shareholder approval at the November 19, 2025 EGM and completion of prescribed legal steps. Investors should note the 53,829,928 shares outstanding as of the Record Date and the internet-first proxy delivery approach; voting outcomes will be disclosed via a Current Report within four business days after the meeting.
FAQ
What is Prothena (PRTA) asking shareholders to approve at the EGM?
When and where is Prothena's EGM scheduled?
Who was eligible to vote and what was the Record Date?
How can shareholders vote on the proposal?
When must shareholders submit director nomination notices for the 2026 AGM?








